Expertise in
10
conditions

Dr. Sachin G. Pai

Oncology
USA Health Children's & Women's Hospital
1700 Center St, 
Mobile, AL 
Clinical Trials:Currently Recruiting for 1 Trial
16 Years of Experience
Expertise in
10
conditions
USA Health Children's & Women's Hospital
1700 Center St, 
Mobile, AL 

Overview

Sachin Pai is an Oncologist practicing medicine in Mobile, Alabama. He has been practicing medicine for over 16 years.

Dr. Pai is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Breast Cancer.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 13 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

USA Health Children's & Women's Hospital
1700 Center St, Mobile, AL 36604

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

20 Total Publications

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: April 16, 2025
Similar Doctors
Expertise in
43
conditions
Expertise in
43
conditions
Referral may be required

Coastal Pharmacy LLC

29653 Anchor Cross Blvd, 
Daphne, AL 
 (12.9 miles away)
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Heller is an Oncologist practicing medicine in Daphne, Alabama. Dr. Heller is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer. Dr. Heller is currently accepting new patients.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

USA Health Providence Hospital

6801 Airport Blvd, 
Mobile, AL 
 (7.3 miles away)
251-633-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nicole Angel is an Oncologist practicing medicine in Mobile, Alabama. Dr. Angel is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Angel is currently accepting new patients.

Expertise in
64
conditions
Expertise in
64
conditions
Referral may be required

Coastal Pharmacy LLC

29653 Anchor Cross Blvd, 
Daphne, AL 
 (12.9 miles away)
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Jones is an Oncologist practicing medicine in Daphne, Alabama. Dr. Jones is highly rated in 64 conditions, according to our data. His clinical expertise encompasses Primary Mediastinal B-Cell Lymphoma (PMBCL), Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Jones is currently accepting new patients.

Frequently Asked Questions about Dr. Sachin G. Pai

How do I make an appointment with Dr. Sachin G. Pai?

You can book an appointment with Dr. Sachin G. Pai by calling their office at 251-990-1850. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sachin G. Pai a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sachin G. Pai is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sachin G. Pai specialize in?

While Dr. Sachin G. Pai is a Oncology, they have specific expertise in Colorectal Cancer, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sachin G. Pai participate in research or clinical trials?

Yes. Dr. Sachin G. Pai has published 20 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Sachin G. Pai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pai's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 49 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile